Kenvue (KVUE) Stock Plunges Amid Tylenol and Talc Fears – What’s Next?
Kenvue shares hit a 52-week low of $15.46 on Oct. 16, 2025, down about 5% in one day and over 27% in the past year. The company faces new UK talcum-powder lawsuits and ongoing FDA scrutiny over Tylenol, while Q2 revenue fell 4% to $3.84 billion. Moody’s affirmed its A1 rating but cut the outlook to negative. Kenvue replaced its CEO in July and launched a strategic review, considering asset sales.